Catalyst Pharmaceuticals, Inc. - Common Stock (CPRX)
23.40
+0.31 (1.34%)
Catalyst Pharmaceuticals, Inc. is a biopharmaceutical company focused on the development and commercialization of innovative therapies for individuals with rare neurological and neuromuscular diseases
The company’s primary emphasis is on conditions like myasthenia gravis, creating targeted treatments that aim to improve patient outcomes and quality of life. Catalyst Pharmaceuticals is committed to advancing its drug pipeline through research, development, and collaboration, striving to address unmet medical needs in the rare disease landscape. With a patient-centered approach, the company aims to transform the treatment paradigm in its specialized therapeutic areas.
![](https://www.chartmill.com/images/uploads/Undervalued_500_264px_webp_74997b3ff2.webp)
Uncover the potential of CATALYST PHARMACEUTICALS INC, an undervalued stock. NASDAQ:CPRX maintains a strong financial position and offers an appealing valuation.
Via Chartmill · February 5, 2025
![](https://cdn.benzinga.com/files/images/story/2025/02/04/4-Stocks-You-Need-To-Buy-Now-for-Consist.jpeg?width=1200&height=800&fit=crop)
Via Benzinga · February 4, 2025
![](https://cdn.benzinga.com/files/images/story/2023/analyst_ratings_image_1.jpeg?width=1200&height=800&fit=crop)
Via Benzinga · February 4, 2025
![](https://www.chartmill.com/images/uploads/Affordable_Growth_500_264px_webp_add6a3aa59.webp)
Investors seeking growth at a reasonable cost should explore CATALYST PHARMACEUTICALS INC (NASDAQCPRX).
Via Chartmill · January 22, 2025
![](https://www.chartmill.com/images/uploads/thumbnail_article_o_neill_9796d922cc.webp)
Exploring CATALYST PHARMACEUTICALS INC (NASDAQCPRX)'s CANSLIM characteristics.
Via Chartmill · January 22, 2025
![](https://www.chartmill.com/images/uploads/thumbnail_article_navellier_3be8c6e05a.webp)
Why CATALYST PHARMACEUTICALS INC (NASDAQCPRX) qualifies as a high growth stock.
Via Chartmill · January 21, 2025
![](https://www.chartmill.com/images/uploads/Strong_Growth_500_264px_webp_8f1ee6ba5b.webp)
Why CATALYST PHARMACEUTICALS INC (NASDAQCPRX) Is a Standout High-Growth Stock in a Consolidation Phase.
Via Chartmill · January 17, 2025
![](https://www.chartmill.com/images/uploads/HGM_Breakout_19d1a7df53.webp)
Delving into CATALYST PHARMACEUTICALS INC (NASDAQCPRX)'s high Growth Prospects.
Via Chartmill · January 17, 2025
![](https://www.chartmill.com/images/uploads/Undervalued_500_264px_webp_74997b3ff2.webp)
CATALYST PHARMACEUTICALS INC (NASDAQCPRX) is a prime example of a stock that offers more than what meets the eye in terms of fundamentals.
Via Chartmill · January 15, 2025
![](https://www.investors.com/wp-content/uploads/2017/05/IRU4.jpg)
One key metric to look for in a stock is an 80-plus Relative Strength Rating. BeiGene stock just hit that mark, with a jump to 84 Wednesday.
Via Investor's Business Daily · January 15, 2025
![](https://www.investors.com/wp-content/uploads/2017/05/IRU1.jpg)
BridgeBio Pharma stock saw a positive improvement to its Relative Strength (RS) Rating on Tuesday, with an increase from 64 to 87.
Via Investor's Business Daily · January 14, 2025
![](https://www.investors.com/wp-content/uploads/2017/05/IRU4.jpg)
On Monday, SpringWorks Therapeutics stock hit a key technical milestone, seeing its Relative Strength Rating jump to 86.
Via Investor's Business Daily · January 13, 2025
![](https://cdn.benzinga.com/files/images/story/2025/01/09/CPRX.png?width=1200&height=800&fit=crop)
Catalyst Pharmaceuticals settles patent litigation with Teva, delaying generic Firdapse launch until 2035. Legal actions against other defendants remain ongoing.
Via Benzinga · January 9, 2025
![](https://www.investors.com/wp-content/uploads/2023/01/Stock-catalystpharma-firdapse-01-company.jpg)
One of Catalyst's key products has protection against a knockoff from Teva until 2035.
Via Investor's Business Daily · January 8, 2025
![](https://www.chartmill.com/images/uploads/Affordable_Growth_500_264px_webp_add6a3aa59.webp)
NASDAQ:CPRX is not too expensive for the growth it is showing.
Via Chartmill · January 1, 2025
![](https://www.chartmill.com/images/uploads/thumbnail_article_o_neill_9796d922cc.webp)
Why the growth investor may take a look at CATALYST PHARMACEUTICALS INC (NASDAQCPRX).
Via Chartmill · January 1, 2025
![](https://www.chartmill.com/images/uploads/thumbnail_article_navellier_3be8c6e05a.webp)
Exploring growth characteristics of CATALYST PHARMACEUTICALS INC (NASDAQCPRX).
Via Chartmill · December 30, 2024
![](https://www.chartmill.com/images/uploads/HGM_Breakout_19d1a7df53.webp)
Why the high growth investor may take a look at CATALYST PHARMACEUTICALS INC (NASDAQCPRX).
Via Chartmill · December 27, 2024
![](https://www.investors.com/wp-content/uploads/2017/05/IRU77.jpg)
Arcellx stock saw a welcome improvement to its Relative Strength (RS) Rating on Friday, with an upgrade from 79 to 82.
Via Investor's Business Daily · December 27, 2024
![](https://www.investors.com/wp-content/uploads/2017/05/IRU6.jpg)
Neurocrine Biosciences stock saw a welcome improvement to its Relative Strength (RS) Rating on Tuesday, with an upgrade from 67 to 71.
Via Investor's Business Daily · December 24, 2024
![](https://www.chartmill.com/images/uploads/Undervalued_500_264px_webp_74997b3ff2.webp)
CATALYST PHARMACEUTICALS INC (NASDAQCPRX) is a prime example of a stock that offers more than what meets the eye in terms of fundamentals.
Via Chartmill · December 24, 2024
![](https://www.chartmill.com/images/uploads/Strong_Growth_500_264px_webp_8f1ee6ba5b.webp)
CATALYST PHARMACEUTICALS INC (NASDAQCPRX), a strong growth stock, setting up for a breakout.
Via Chartmill · December 17, 2024
![](https://www.investors.com/wp-content/uploads/2017/05/IRU77.jpg)
NewAmsterdam Pharma stock saw a welcome improvement to its Relative Strength (RS) Rating on Wednesday, rising from 74 to 95.
Via Investor's Business Daily · December 11, 2024
![](https://www.chartmill.com/images/uploads/Affordable_Growth_500_264px_webp_add6a3aa59.webp)
Investors seeking growth at a reasonable cost should explore CATALYST PHARMACEUTICALS INC (NASDAQCPRX).
Via Chartmill · December 11, 2024
![](https://www.chartmill.com/images/uploads/thumbnail_article_o_neill_9796d922cc.webp)
Exploring CATALYST PHARMACEUTICALS INC (NASDAQCPRX)'s growth characteristics.
Via Chartmill · December 11, 2024